An open study of inactivated hepatitis A vaccine (VAQTA) in Taiwanese healthy adult volunteers: Safety, tolerability, and immunogenicity
Journal
Journal of Microbiology, Immunology and Infection
Journal Volume
37
Journal Issue
4
Pages
216-218
Date Issued
2004
Author(s)
Abstract
The safety, tolerability and immunogenicity of inactivated hepatitis A vaccine (VAQTA, Merck and Co. Inc., West Point, PA, USA) were investigated in 28 seronegative healthy adult volunteers. The age range was 25-35 years, and the mean age was 29 years. Two doses of the vaccine, each containing 50 U of hepatitis A virus antigen, were administered into the deltoid region 24 weeks apart. No serious vaccine-related adverse reactions were reported. Four weeks after the first dose, the geometric mean titer (GMT) was 150 mlU/mL, and the seroconversion rate was 100%. Twenty eight weeks after the first dose (4 weeks following the second dose), the GMT was 4576 mIU/mL. This study demonstrated that VAQTA is safe and highly immunogenic in healthy young adults in Taiwan.
SDGs
Other Subjects
hepatitis A antigen; hepatitis A vaccine; inactivated vaccine; adult; antibody blood level; antibody titer; article; drug dose regimen; drug efficacy; drug safety; drug screening; drug tolerability; erythema; fatigue; female; hepatitis A; Hepatitis A virus; human; human experiment; immunogenicity; injection pain; male; normal human; open study; seroconversion; Taiwan; Adult; Antibodies, Viral; Drug Tolerance; Female; Hepatitis A Vaccines; Hepatitis A virus; Humans; Male; Safety; Time Factors; Vaccines, Inactivated
Type
journal article